Selank 10mg

• 1. Overview
• 2. Biochemical Characteristics
• 3. Research Applications
• 4. Pathway / Mechanistic Context
• 5. Preclinical Research Summary
• 6. Form & Analytical Testing
• 7. Referenced Citations
• 8. RUO Disclaimer

Overview

Selank is a synthetic heptapeptide built on the tuftsin backbone (Thr-Lys-Pro-Arg) with a C-terminal Pro-Gly-Pro extension added for enzymatic stability. Tuftsin is a naturally occurring immunomodulatory tetrapeptide. The Pro-Gly-Pro appendage is the same stabilization strategy used in Semax — same structural modification, different parent sequence. Where Semax is derived from an ACTH fragment, Selank derives from tuftsin, giving it a separate biochemical identity and a distinct research literature.

Published in vitro research on Selank has focused on immune signaling pathways, GABA receptor-related gene expression, and enkephalin metabolism in cell culture systems. The compound's enzymatic stability has been characterized through enzyme kinetics work, confirming that the Pro-Gly-Pro modification confers aminopeptidase resistance in a manner consistent with the Semax literature.

Biochemical Characteristics

Selank's heptapeptide sequence — Thr-Lys-Pro-Arg-Pro-Gly-Pro — consists of the native tuftsin tetrapeptide (Thr-Lys-Pro-Arg) extended by three additional residues at the C-terminus. The parent tetrapeptide tuftsin is a fragment of the Fc region of IgG, naturally cleaved by leucine aminopeptidase and carboxypeptidase B. It has documented immunomodulatory properties in published research, including interactions with phagocyte receptors and cytokine expression in leukocyte assays.

The synthetic Pro-Gly-Pro extension modifies the C-terminal structure in a way that interferes with aminopeptidase cleavage, extending the half-life of the compound in enzymatic environments compared to native tuftsin. Molecular formula C₃₃H₅₇N₁₁O₉, molecular weight 751.87 g/mol, CAS 129954-34-3, PubChem CID 11975633.

Research Applications

• Immune signaling pathway studies examining cytokine expression profiles in cell-based assays
• Immunoglobulin production research in leukocyte and lymphocyte culture models
• GABA receptor-related gene expression studies in neural cell culture systems
• Enkephalin metabolism research examining opioid peptide biosynthesis pathways
• Enzyme kinetics studies characterizing aminopeptidase resistance of the Pro-Gly-Pro modification
• Comparative tuftsin vs. Selank receptor interaction studies in cell-based models
• Parallel neuropeptide research protocols alongside Semax in cell culture systems

All applications are restricted to non-clinical laboratory research environments.

Pathway / Mechanistic Context

The immunomodulatory activity attributed to Selank in published research traces mechanistically to the tuftsin backbone. Tuftsin interacts with receptors on phagocytic cells including monocytes and neutrophils, and this receptor engagement has been linked in published work to downstream cytokine expression changes in cell culture. Selank studies have built on this framework, examining whether the Pro-Gly-Pro extension alters or preserves the tuftsin-receptor interaction profile.

The GABA receptor-related gene expression research represents a second mechanistic thread in the Selank literature. In vitro studies have used mRNA expression profiling to characterize how Selank exposure affects expression patterns of genes associated with GABAergic signaling in neural cell lines. This line of research is methodologically distinct from the immune signaling work and reflects the compound's cross-pathway research relevance.

Enkephalin metabolism studies form a third area. Published work has examined Selank's influence on enkephalin-degrading enzymes in cell systems, with researchers documenting changes in enkephalin peptide levels following Selank treatment in cell culture assays. The mechanism connecting tuftsin analog structure to enkephalin system interactions remains an active area of in vitro investigation.

Preclinical Research Summary

Selank's published research record dates back several decades, originating from work at the Institute of Molecular Genetics of the Russian Academy of Sciences. Early published studies focused on establishing the compound's stability advantage over native tuftsin and characterizing its immune pathway interactions in cell-based models. Zozulya et al. (2001, CNS Drug Reviews) provided a comprehensive early review of the pharmacological properties attributed to Selank in published research, covering immune signaling and CNS-related pathway data.

Subsequent published research expanded into gene expression methodology. Studies examining mRNA profiles in cell systems treated with Selank documented changes in expression patterns for genes associated with GABA signaling and immune function. Semenova et al. (2010) documented behavioral and neurochemical outcomes in animal model research. The compound's enzymatic stability profile has been validated across multiple published studies using comparative degradation assays.

Form & Analytical Testing

Selank 10mg is supplied as research-grade lyophilized powder. Each batch is submitted to Vanguard Laboratory for conformity testing using a 5-vial protocol. The 7-panel protocol covers identity verification (mass spectrometry), purity analysis (≥98% via HPLC), net content verification (10mg confirmed), endotoxin levels, heavy metals screening, sterility, and overall conformity assessment. Russian-developed peptide, Chinese-manufactured, American-tested. Vanguard verifies what's in the vial regardless of origin. Batch-specific COAs are published on our COA Library and linked via QR code on each vial.

Referenced Citations

1. Zozulya AA et al., “Tuftsin and selank: the peptide family with immunomodulatory and anxiolytic activity,” CNS Drug Rev, 2001 7(2):143–162.
2. Uchakina ON et al., “Immunomodulatory effects of selank in patients with anxiety-asthenic disorders,” Zh Nevrol Psikhiatr Im S S Korsakova, 2008 108(5):71–75.
3. Semenova TP et al., “Comparison of the effects of selank and tuftsin on the metabolism of serotonin in the brain of rats pretreated with PCPA,” Bull Exp Biol Med, 2010 150(3):269–271.
4. Kozlovskaya MM et al., “Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress,” Bull Exp Biol Med, 2006 142(5):565–568.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

RUO Disclaimer

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals.

This product is not a drug, food, or cosmetic and may not be misbranded, misused, or mislabeled as a drug, food, or cosmetic. No statements on this website have been evaluated by the FDA. You must be 21 years or older to purchase.

Batch COA: In Progress

This batch is currently undergoing conformity testing at Vanguard Laboratory. The full Certificate of Analysis — covering identity, purity (≥98% via HPLC), net content (10mg confirmed), endotoxins, heavy metals, and sterility — will be published here and linked via QR code on each vial upon completion.

We don't ship product before results are in. When the COA is live, you'll find it here and on our COA Library.